Factor VIII (FVIII) inhibitors are antibodies that develop against FVIII, either endogenous FVIII (as in the case of acquired hemophilia A (AHA)) or exogenous FVIII (as in the case of congenital hemophilia A (CHA)) [1,2,3,4,5]. Here, F8 is linked to autoimmune hemolytic anemia.